Chronic Myeloid Leukemia
Chronic Myeloid Leukemia
The latest news, research, and perspectives in chronic myeloid leukemia (CML). CML is caused by the BCR-ABL1 fusion gene, which is formed by a translocation between chromosomes 9 and 22 (the Philadelphia chromosome), that produces abnormal proteins leading to the development of leukemic cells.
Advertisement
Melissa BadamoChronic Myeloid Leukemia | January 24, 2025
Asciminib showed superior safety and efficacy compared with standard-of-care, second-generation, investigator-selected TKIs.
Read More
Nichole TuckerChronic Myeloid Leukemia | January 28, 2025
Pirtobrutinib cut disease progression/death risk by 46% vs IdealaR/BR in heavily pretreated relapsed/refractory CLL/SLL.
Melissa BadamoAcute Lymphoblastic Leukemia | January 27, 2025
The US cancer mortality rate has declined by 34%, but the incidence of leukemia and other malignancies is increasing.
Andrew MorenoAcute Lymphoblastic Leukemia | January 22, 2025
A real-world study found blinatumomab plus ponatinib as more likely to be effective if used in earlier lines of therapy.
Andrew MorenoAcute Lymphoblastic Leukemia | January 10, 2025
Issues addressed include mandatory versus optional biopsy, informed consent, and safety in both adult and pediatric patients.
Blood Cancers Today Staff WritersChronic Myeloid Leukemia | January 7, 2025
The study used a standard 3+3 dose escalation design to evaluate the results of SYNCAR-001 plus STK-009.
Advertisement
Andrew MorenoChronic Myeloid Leukemia | November 13, 2024
Adverse events were common in patients with CML receiving first- or second-generation tyrosine kinase inhibitors.
Melissa BadamoChronic Myeloid Leukemia | October 30, 2024
The approval is based on results of the ASC4FIRST trial, which compared asciminib versus investigator-selected TKIs.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Ponatinib demonstrated long-term efficacy and manageable safety in patients with highly resistant, chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Achieving deep molecular response has allowed for treatment discontinuation, making TFR a main goal of therapy.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Olverembatinib was well tolerated and showed strong antileukemic activity in patients with chronic phase CML.
Melissa BadamoChronic Myeloid Leukemia | September 27, 2024
Asciminib continues to demonstrate favorable safety and tolerability compared to TKIs in patients with chronic phase CML.
Rebecca AraujoChronic Myeloid Leukemia | September 23, 2024
Age ≥65 years, arrhythmia, and cardiogenic shock were associated with a significantly higher rate of acute heart failure.
Jorge Cortes, MDChronic Myeloid Leukemia | June 14, 2024
The rate of response was “significantly higher” with asciminib compared with tyrosine kinase inhibitors.
Sangeetha Venugopal, MDChronic Myeloid Leukemia | June 7, 2024
Sangeetha Venugopal, MD, engages outstanding issues in chronic myeloid leukemia treatment research.
Elias Jabbour, MDPrint | May 22, 2024
In this executive editor's message, Elias Jabbour, MD, writes about redefining leukemias as curable or less curable.
Melissa BadamoPrint | April 30, 2024
Palliative care facilitates communication and helps with symptom management, the researchers noted.
Gwen Nichols, MDAcute Myeloid Leukemia | March 5, 2024
The goal of PedAL is to establish a data-driven developmental therapeutics program.
Katie KoskoChronic Myeloid Leukemia | March 5, 2024
The trial's treatment regimen included single-agent dasatinib for the first three months, followed by venetoclax.
Melissa BadamoAcute Lymphoblastic Leukemia | December 4, 2023
The study determined the maximum tolerated dose of asciminib with dasatinib and prednisone.
Advertisement
Advertisement